Figure 1
Figure 1. Flow cytometric analysis of engraftment and differentiation of in vitro–derived CD34+ CD7++ CD5− (proT1)- and CD34+ CD7++ CD5+ (proT2)-cells in immunodeficient mice. (A) Human UCB CD34+CD38−/lo cells were differentiated on OP9-DL1 cells for 10 days and CD34+CD7++ CD5− (proT1)- and CD34+ CD7++ CD5+ (proT2)-cells were sorted by flow cytometry. (B) Neonatal NSG mice were injected intrahepatically with 2.0 × 105 cells of either subset (n ≥ 8 mice/group). Thymuses were harvested after 4 weeks and stained for CD45, CD4, CD8, and CD3. The percentage of human CD45+ cells present in the thymus of NSG mice transplanted with proT1-cells (average thymus cellularity 27.6 × 104 ± 6.6 × 104) or proT2 cells (average thymus cellularity 31.6 × 104 ± 4.0 × 104) are shown. CD4, CD8, and CD3 cell surface expressions are shown on CD45+-gated thymocytes. The results shown are representative of at least 3 independent experiments. SSC, side scatter.

Flow cytometric analysis of engraftment and differentiation of in vitroderived CD34+CD7++CD5(proT1)- and CD34+CD7++CD5+(proT2)-cells in immunodeficient mice. (A) Human UCB CD34+CD38−/lo cells were differentiated on OP9-DL1 cells for 10 days and CD34+CD7++ CD5 (proT1)- and CD34+ CD7++ CD5+ (proT2)-cells were sorted by flow cytometry. (B) Neonatal NSG mice were injected intrahepatically with 2.0 × 105 cells of either subset (n ≥ 8 mice/group). Thymuses were harvested after 4 weeks and stained for CD45, CD4, CD8, and CD3. The percentage of human CD45+ cells present in the thymus of NSG mice transplanted with proT1-cells (average thymus cellularity 27.6 × 104 ± 6.6 × 104) or proT2 cells (average thymus cellularity 31.6 × 104 ± 4.0 × 104) are shown. CD4, CD8, and CD3 cell surface expressions are shown on CD45+-gated thymocytes. The results shown are representative of at least 3 independent experiments. SSC, side scatter.

Close Modal

or Create an Account

Close Modal
Close Modal